The molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in the Czech Republic.

Tkadlec J., V. Capek, M. Brajerova, E. Smelikova, O. Melter, T. Bergerova, S. Polivkova, M. Balejova, M. Hanslianova, D. Fackova, K. Neradova, R. Tejkalova, I. Vagnerova, N. Bartonikova, E. Chmelarova, P. Drevinek, M. Krutova. Journal of Antimicrobial Chemotherapy. 2021 Jan 1;76(1):55-64. doi: 10.1093/jac/dkaa404. IF: 5.44

Mgr. Jan Tkadlec, Ph.D.

Mgr. Jan Tkadlec, Ph.D.

Department of Medical Microbiology


Objectives: To gain data on the current molecular epidemiology and resistance of MRSA in the Czech Republic.

Methods: Between September 2017 and January 2018, a total of 441 single-patient MRSA isolates were collected from 11 Czech hospitals and analysed by spa typing, SCCmec typing, antibiotic susceptibility testing, detection of the PVL toxin and the arcA gene.

Results: Of all MRSA isolates, 81.41% (n = 359) belonged to the CC5-MRSA clone represented by the spa types t003 (n = 136), t586 (n = 92), t014 (n = 81), t002 (n = 20) and other spa types (n = 30); a majority of the CC5 isolates (n = 348, 96.94%) carried SCCmec type II. The occurrence of CC5-MRSA was more likely in older inpatients and associated with a healthcare origin (P < 0.001). The CC5-MRSA isolates were resistant to more antimicrobial drugs compared with the other MRSAs (P < 0.001). Interestingly, t586 was detected in blood samples more often than the other spa types and, contrary to other spa types belonging to CC5-MRSA, t586 was not associated with patients of advanced age. Other frequently found lineages were CC8 (n = 17), CC398 (n = 11) and CC59 (n = 10). The presence of the PVL was detected in 8.62% (n = 38) of the MRSA isolates.

Conclusions: The healthcare-associated CC5-MRSA-II lineage (t003, t586, t014) was found to be predominant in the Czech Republic. t586 is a newly emerging spa type in the Czech Republic, yet reported rarely in other countries. Our observations stress the need for MRSA surveillance in the Czech Republic in order to monitor changes in MRSA epidemiology.

Created: 19. 2. 2021 / Modified: 31. 5. 2021 / Responsible person: Mgr. Ing. Tereza Kůstková